AEDH-MT study is multi-center, prospective, randomized (1:1) controlled trial designed to evaluate that additional MMA embolization in managed patients in conservatively treated patients with acute epidural hematoma can reduce the proportion of epidural hematoma progression to requiring craniotomy surgery.AEDH-MT is a clinical study sponsored by Shanghai Changhai Hospital , and has completed registration by Clinical Trials（ClinicalTrials.gov Identifier: NCT06292585).

MILD-MT trial is an investigator initiated, multicenter, prospective, randomized, controlled, open label, blinded endpoint assessment (PROBE) clinical trial. MILD-MT trial aims to explore the efficacy and safety of endovascular treatment in patients with mild ischemic stroke caused by acute anterior circulation large vessel occlusion based on perfusion imaging screening. (ClinicalTrials.gov Identifier: NCT06179017)

DIRECT-MT trial is a multicenter randomized clinical trial investigating the effect of direct intra-arterial thrombectomy compared with i.v. alteplase followed by intra-arterial thrombectomy, on functional outcome in patients with acute ischemic stroke, caused by an anterior circulation large vessel occlusion that is confirmed by neuro-imaging. DIRECT-MT is one of the randomized clinical trials that will be conducted by National Health and Family Planning Commission of the People's Republic of China (ClinicalTrials.gov Identifier: NCT03469206 ) .

View more

The Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED-MT) is an international, multicenter, prospective, randomized, open, blinded end-point assessed (PROBE) clinical platform trial, with the main acute treatment trial of different approaches to BP control and two nested substudy clinical trials evaluating different approaches to secondary prevention, in this high-risk stroke population. The objective was to determine the effectiveness of more intensive blood pressure (BP) lowering target (<120 mmHg) as compared to a higher BP management target (140-180mmHg) on functional outcome in patients who have had successful recanalization with mechanical thrombectomy (MT) for acute ischemic stroke (AIS) due to large vessel occlusion (LVO). (ClinicalTrials.gov Identifier: NCT04140110)

View more

MAGIC-MT study is multi-center, prospective, randomized (1:1) controlled trial designed to show that additional MMA embolization with Onyx in patients with non-acute symptomatic subdural hematoma(SDH) results in reduced hematoma recurrence in surgically treated patients/ reduced hematoma progression in conservatively managed patients. MAGIC-MT is a clinical study jointly sponsored by Huashan Hospital affiliated to Fudan University and Shanghai Changhai Hospital , and has completed registration by Clinical Trials（ClinicalTrials.gov Identifier: NCT04700345

View more

LATE-MT trial is an investigator initiated and adaptive group sequential design conducted, multicenter, prospective, randomized, controlled, open label, blinded endpoint assessment (PROBE) clinical trial. LATE-MT trial aims to determine that compared with standard medical care without MT, performing MT in a time window that exceeds 24 hours after last seen well, is superior on the functional outcome in AIS patients due to LVO who have been carefully selected by clinical and imaging criteria. (ClinicalTrials.gov Identifier: NCT05326932)

PROTECT-MT trial is an investigator initiated, multicenter, prospective, randomized, controlled, open label, blinded endpoint assessment (PROBE) clinical trial. PROTECT-MT trial aims to determine the effectiveness of balloon guide catheter(BGC) as compared to standard guide catheter on functional outcome in patients with acute ischemic stroke due to anterior circulation large vessel occlusion. (ClinicalTrials.gov Identifier: NCT05592054)